Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Open in Screener

MREO

Mereo Biopharma Group Plc ADR

Feb 13 • 04:00PM ET

0.3719

-0.0168 -4.32 %

Healthcare • Biotechnology • United Kingdom • NASD

Peers: SRPT FATE KURA ADVM RIGL XERS IMUX PRQR CLSD MTEM

| Held by: IDNA GWX BBC

Index	-	P/E	-	EPS (ttm)	-0.26	Insider Own	12.78%	Shs Outstand	159.10M	Perf Week	-12.39%
Market Cap	59.17M	Forward P/E	-	EPS next Y	-0.03	Insider Trans	0.00%	Shs Float	138.76M	Perf Month	-48.10%
Enterprise Value	10.87M	PEG	-	EPS next Q	-0.01	Inst Own	67.18%	Short Float	9.40%	Perf Quarter	-79.79%
Income	-41.69M	P/S	116.02	EPS this Y	1.00%	Inst Trans	-4.41%	Short Ratio	0.88	Perf Half Y	-78.25%
Sales	0.51M	P/B	1.27	EPS next Y	42.93%	ROA	-58.57%	Short Interest	13.04M	Perf YTD	-10.75%
Book/sh	0.29	P/C	1.21	EPS next 5Y	12.64%	ROE	-69.98%	52W High	3.05 -87.81%	Perf Year	-87.09%
Cash/sh	0.31	P/FCF	-	EPS past 3/5Y	- 34.82%	ROIC	-89.46%	52W Low	0.20 85.95%	Perf 3Y	-64.24%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	73.60%	Volatility	11.35% 12.50%	Perf 5Y	-88.45%
Dividend TTM	-	EV/Sales	21.31	EPS Y/Y TTM	-5.44%	Oper. Margin	-9340.40%	ATR (14)	0.08	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	8.71	Sales Y/Y TTM	-	Profit Margin	-8240.08%	RSI (14)	31.54	Recom	1.62
Dividend Gr. 3/5Y	- -	Current Ratio	8.71	EPS Q/Q	55.69%	SMA20	-18.31%	Beta	0.28	Target Price	3.44
Payout	-	Debt/Eq	0.01	Sales Q/Q	-	SMA50	-64.16%	Rel Volume	0.13	Prev Close	0.39
Employees	36	LT Debt/Eq	0.00	Earnings	Nov 10 AMC	SMA200	-79.33%	Avg Volume	14.79M	Price	0.37
IPO	Apr 24, 2019	Option/Short	Yes / Yes	EPS/Sales Surpr.	-75.44% -98.29%	Trades		Volume	1,869,275	Change	-4.32%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-30-25	Downgrade	Jefferies	Buy → Hold	$0.50
Mar-27-25	Initiated	JP Morgan	Overweight	$7
Dec-06-24	Initiated	Jefferies	Buy	$7
Jun-13-24	Initiated	Robert W. Baird	Outperform	$8
Oct-13-23	Resumed	BTIG Research	Buy	$4
Aug-12-22	Initiated	Cantor Fitzgerald	Overweight	$4
May-05-21	Initiated	BTIG Research	Buy	$10
Apr-05-21	Initiated	Needham	Buy	$10

Today 11:23AM	Shareholders who lost money in shares of Mereo BioPharma Group PLC (NASDAQ: MREO) should contact Wolf Haldenstein immediately (PR Newswire)
Feb-09-26 03:29AM	Mereo BioPharma Group plc Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - MREO (PR Newswire) -8.60%
Feb-06-26 07:30AM	Mereo BioPharma Group plc Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights MREO (Business Wire) +13.20%
Jan-12-26 08:00AM	Mereo BioPharma Provides Corporate Update (GlobeNewswire) +14.75%
Dec-31-25 09:40AM	DigitalBridge downgraded, Commvault initiated: Wall Streets top analyst calls (TipRanks) +12.47%
12:39PM	Loading…
Dec-30-25 12:39PM	Why Ultragenyx Stock Dropped 42% and What Comes Next (Barrons.com) +29.82%
11:00AM	RARE, MREO Tank as Osteogenesis Study Fails to Meet Primary Endpoint (Zacks)
09:36AM	DigitalBridge downgraded, Commvault initiated: Wall Street's top analyst calls (The Fly)
Dec-29-25 01:05PM	These biotech stocks are getting hammered by shocking brittle-bone treatment study results (MarketWatch) -87.65%
08:31AM	Mereo BioPharma Announces Phase 3 ORBIT and COSMIC Results for Setrusumab (UX143) in Osteogenesis Imperfecta (GlobeNewswire)
Nov-10-25 04:01PM	Mereo BioPharma Reports Third Quarter 2025 Financial Results and Provides Corporate Highlights (GlobeNewswire) +5.65%
Aug-19-25 08:30AM	ashibio Expands Clinical Pipeline with Vantictumab, a First-In-Class Antibody for Autosomal Dominant Osteopetrosis Type 2 (Business Wire)
Aug-12-25 07:35AM	Mereo BioPharma Reports Second Quarter 2025 Financial Results and Provides Corporate Highlights (GlobeNewswire) +9.21%
Aug-11-25 07:45AM	Mereo BioPharma Group (MREO) Announced Progress in the Phase 3 Orbit Study Testing UX143 (Insider Monkey)
Jul-10-25 10:37AM	Biotech Stock Ultragenyx Is Falling on Unsatisfying Trial Update (Barrons.com) -42.52%
10:34AM	Loading…
10:34AM	Ultragenyx, Mereo Hammered For Their Surprise Miss In Brittle Bone Disease (Investor's Business Daily)
10:17AM	RARE, MREO Fall as Osteogenesis Study Likely to Continue Till Year End (Zacks)
07:52AM	Kellogg shares soar on buyout talk, and other early market movers (MarketWatch)
Jul-09-25 04:05PM	Ultragenyx and Mereo BioPharma Announce UX143 Phase 3 Orbit Study for Osteogenesis Imperfecta Progressing to Final Analysis (GlobeNewswire)
May-13-25 07:30AM	Mereo BioPharma Reports First Quarter 2025 Financial Results and Provides Corporate Highlights (GlobeNewswire) -7.20%
Apr-16-25 03:00PM	Mereo BioPharma Group plc (MREO): A Bull Case Theory (Insider Monkey) +6.50%
11:23AM	Is Mereo BioPharma Group (NASDAQ:MREO) the Best Biotech Penny Stock to Buy According to Hedge Funds? (Insider Monkey)
Mar-26-25 07:30AM	Mereo BioPharma Reports Full Year 2024 Financial Results and Provides Corporate Highlights (GlobeNewswire)
Mar-20-25 12:00PM	MEREO BIOPHARMA (MREO) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
Mar-05-25 07:30AM	Mereo BioPharma to Participate in Fireside Chat at the Leerink Partners Global Healthcare Conference (GlobeNewswire)
Feb-11-25 11:00AM	Mereo Insurance forays into reinsurance market (Life Insurance International)
Feb-10-25 02:12PM	Ex-AIG Chief Secures $700 Million for Mereo Reinsurance Startup (Bloomberg)
Jan-12-25 11:05AM	Mereo BioPharma Provides Update on Lead Clinical Programs (GlobeNewswire)
Jan-07-25 07:30AM	Mereo BioPharma to Present at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-30-24 02:50PM	Why Mereo BioPharma (MREO) Is One of the Best Biotech Penny Stocks to Invest in Now? (Insider Monkey) -5.63%
05:20AM	Loading…
Dec-07-24 05:20AM	Mereo BioPharma initiated with a Buy at Jefferies (TipRanks)
Dec-06-24 01:18PM	Mereo BioPharma Stock Climbs Following Jefferies' Buy Rating, Upside Potential of 89% (GuruFocus.com) +8.65%
Nov-14-24 07:30AM	Mereo BioPharma to Participate in Fireside Chat at the Jefferies London Healthcare Conference (GlobeNewswire) -5.68%
Nov-12-24 07:30AM	Mereo BioPharma Reports Third Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Oct-16-24 09:06AM	Is Mereo BioPharma Group (MREO) the Hottest Penny Stock to Invest in According to Hedge Funds? (Insider Monkey)
Sep-18-24 08:21AM	Mereo BioPharma Group plc (MREO): A Bull Case Theory (Insider Monkey) +6.84%
Sep-12-24 05:35PM	Mereo BioPharma to Participate in Fireside Chat at the 2024 Cantor Global Healthcare Conference (GlobeNewswire) -5.79%
Aug-13-24 08:00AM	Mereo BioPharma Reports Second Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Jun-15-24 11:42PM	Street calls of the week: Upgrade for Shopify; downgrades for AMD, Paramount (Investing.com)
Jun-14-24 07:50AM	Mereo BioPharma Announces Pricing of $50 Million Underwritten Registered Direct Offering of American Depository Shares, Priced At-the-Market (GlobeNewswire) +6.52%
Jun-12-24 07:45AM	Ultragenyx, Mereo drug reduces fractures in bone disorder study (BioPharma Dive) +8.81%
Jun-11-24 05:47PM	Ultragenyx and Mereo BioPharma Announce New Phase 2 Data from Phase 2/3 Orbit Study Demonstrating Sustained Reductions in Fracture Rates Following Treatment with Setrusumab (UX143) in Patients with Osteogenesis Imperfecta (OI) (GlobeNewswire)
May-30-24 07:30AM	Mereo BioPharma to Participate in Fireside Chat at the Jefferies Global Healthcare Conference (GlobeNewswire) +5.90%
May-15-24 04:01PM	Mereo BioPharma Reports First Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire) +7.09%
Apr-12-24 09:35AM	MEREO BIOPHARMA (MREO) Loses -12.74% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
Apr-03-24 07:30AM	Mereo BioPharma to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-27-24 05:27PM	Mereo BioPharma Group PLC (MREO) Announces Full Year 2023 Financial Results (GuruFocus.com) +10.00%
04:01PM	Mereo BioPharma Reports Full Year 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Mar-05-24 07:30AM	Mereo BioPharma to Participate in Fireside Chat at the Leerink Partners Global Biopharma Conference (GlobeNewswire)
Feb-16-24 03:57AM	15 Top Performing European Stocks So Far in 2024 (Insider Monkey)
Jan-08-24 07:00AM	Mereo BioPharma Provides Update on Pipeline Progress and Corporate Developments (GlobeNewswire)
Dec-19-23 11:21AM	Hedge Funds Say These Penny Stocks Are Poised to Explode (Insider Monkey)
Nov-03-23 11:43AM	Ultragenyx (RARE) Q3 Earnings and Revenues Miss Estimates (Zacks)
Oct-23-23 04:01PM	Mereo BioPharma Reports on Recent Program Developments and Provides Financial Update (GlobeNewswire) -7.89%
Oct-14-23 04:30PM	Ultragenyx and Mereo BioPharma Announce Interim Phase 2 Data from Phase 2/3 Orbit Study Demonstrating Setrusumab (UX143) Significantly Reduced Fracture Rates in Patients with Osteogenesis Imperfecta (OI) (GlobeNewswire)
Oct-09-23 08:00AM	Ultragenyx to Present Setrusumab (UX143) Update at ASBMR 2023 Including New Data from Phase 2/3 Orbit Study in Osteogenesis Imperfecta (OI) (GlobeNewswire)
Sep-21-23 07:00AM	Mereo BioPharma to Participate in Fireside Chat at the 2023 Cantor Global Healthcare Conference (GlobeNewswire) -5.67%
Sep-07-23 07:30AM	Mereo BioPharma Reports Interim Financial Results for the Six Months Ended June 30, 2023 and Provides Corporate Update (GlobeNewswire)
Aug-10-23 11:04PM	BAKER BROS. ADVISORS LP Acquires Significant Stake in Mereo BioPharma Group PLC (GuruFocus.com) -6.30%
Aug-04-23 08:12AM	Ultragenyx (RARE) Q2 Loss Wider Than Expected, Revenues Beat (Zacks)
Jul-07-23 07:46AM	Ultragenyx (RARE) Doses First Patients in Bone Disease Studies (Zacks) +7.32%
Jul-06-23 08:00AM	Ultragenyx Announces First Patients Dosed in Phase 3 Program Evaluating Setrusumab (UX143) for the Treatment of Osteogenesis Imperfecta (OI) (GlobeNewswire)
May-31-23 07:00AM	Mereo BioPharma to Present at the Jefferies Healthcare Conference (GlobeNewswire)
May-23-23 01:43PM	Phase 2 Data from ASTRAEUS Trial of Mereo BioPharmas Alvelestat in Alpha-1 Antitrypsin Deficiency-associated Lung Disease Presented at the 2023 American Thoracic Society International Conference (GlobeNewswire) -5.47%
May-08-23 12:46PM	Mereo BioPharma Regains Compliance with Nasdaq Minimum Bid Price Requirement (GlobeNewswire)
May-05-23 04:06PM	Mereo BioPharma Announces Listing Transfer to Nasdaq Capital Market (GlobeNewswire)
Apr-21-23 12:00PM	What Makes MEREO BIOPHARMA (MREO) a Strong Momentum Stock: Buy Now? (Zacks) -5.72%
Apr-13-23 08:00AM	Mereo BioPharma to Participate in Fireside Chat at the 22nd Annual Needham Healthcare Conference (GlobeNewswire)
Mar-28-23 04:30PM	Mereo BioPharma Reports Full Year 2022 Financial Results and Recent Highlights (GlobeNewswire)
Mar-21-23 06:30AM	Mereo BioPharma Provides Regulatory Updates on Alvelestat for the Treatment of Alpha-1-Antitrypsin Deficiency-Associated Lung Disease (GlobeNewswire) +16.89%
Feb-08-23 07:00AM	Mereo BioPharma to Participate in Fireside Chat at the SVB Securities Global Biopharma Conference (GlobeNewswire)
Jan-10-23 05:35AM	Positive week for Mereo BioPharma Group plc (NASDAQ:MREO) hedge funds investors who lost 33% over the past year (Simply Wall St.) -7.12%
Nov-15-22 09:35AM	MEREO BIOPHARMA (MREO) Loses 25.2% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks) +5.92%
Nov-08-22 07:00AM	Mereo BioPharma to Participate in Fireside Chat at the Jefferies London Healthcare Conference (GlobeNewswire)
Nov-02-22 04:01PM	Mereo BioPharma Received Notification of Nasdaq Minimum Bid Price Deficiency (GlobeNewswire) -6.97% -8.76%
Oct-28-22 07:00AM	Mereo BioPharma Reaches Cooperation Agreement with Rubric Capital Management (GlobeNewswire)
Oct-24-22 04:30PM	Mereo BioPharma to Host Alvelestat R&D Update Call on October 31, 2022 (GlobeNewswire)
Oct-21-22 07:00AM	Mereo BioPharma Files Shareholder Circular for Upcoming General Meeting (GlobeNewswire)
Oct-18-22 11:58AM	Rubric Capital Management Comments on Mereo BioPharma Updated Operating Plan (Business Wire)
07:00AM	Mereo BioPharma Announces Updated Operating Plan to Maximize Shareholder Value (GlobeNewswire)
Oct-17-22 07:00AM	Mereo BioPharma Receives FDA Fast Track Designation for Alvelestat for Treatment of Alpha-1 Antitrypsin Deficiency (AATD)-associated Lung Disease (GlobeNewswire)
Oct-03-22 05:00PM	Mereo BioPharma Confirms Receipt of a Valid Notice Requiring it to Convene a General Meeting of Shareholders (GlobeNewswire) +7.85%
09:00AM	Rubric Capital Management Increases Slate of Proposed Mereo BioPharma Director Nominees to Five (Business Wire)
Sep-28-22 09:21AM	Chinese Billionaire Zhang Lei is Selling These 10 Stocks (Insider Monkey)
Sep-26-22 07:00AM	Mereo BioPharma Offered to Settle Proxy Contest with Rubric Capital Management by Putting Rubric Principal and Second New Director on the Board (GlobeNewswire)
Sep-14-22 09:00AM	Rubric Capital Management Issues Open Letter to Mereo BioPharma Shareholders (Business Wire)
Sep-12-22 08:00AM	Mereo BioPharma Reports Clinical Update and Interim Biomarker Analysis Presented at ESMO 2022 from ACTIVATE Phase 1b/2 Open Label Study of Etigilimab (Anti-TIGIT Antibody MPH-313) plus Nivolumab (Anti-PD-1 Antibody) in Solid Tumors (GlobeNewswire)
Sep-09-22 08:22PM	Ultragenyx and Mereo BioPharma to Present Setrusumab Data Update at ASBMR (GlobeNewswire) +5.94%
Aug-31-22 07:00AM	Mereo BioPharma Sends Letter to Rubric Capital Management (GlobeNewswire)
Aug-22-22 04:00AM	Mereo BioPharma Sends Letter to Rubric Capital Management (GlobeNewswire)
Jul-05-22 04:01PM	Mereo BioPharma Regains Compliance with Nasdaq Minimum Bid Price Requirement (GlobeNewswire) -6.52%
Jun-21-22 08:30AM	CEOs of NIO, NEXCF, MREO, and AIMLF Advancing Next Wave of Multi-Billion Dollar Growth Opportunities in Web 3.0, Wearables, Pharma, and Electric Vehicles. (GlobeNewswire) +30.00%
Jun-20-22 10:36AM	Mereo BioPharma (MREO) Up as AstraZeneca Reportedly Eyes Buyout (Zacks)
Jun-17-22 05:30PM	Mereo BioPharm and Theseus Pharmaceuticals See Action From Activist Investors (Barrons.com) +62.50% +30.00%
03:53PM	AstraZeneca weighs bid for Mereo, Carnival Cruises partners with MGM, Devon Energy stock plunges (Yahoo Finance Video)
10:21AM	Why Mereo BioPharma Shares Are Jumping Today (Benzinga)
03:44AM	AstraZeneca weighing bid for Mereo BioPharma: report (MarketWatch)
Jun-02-22 08:00AM	Mereo BioPharma To Present Data Update for the Phase 1b/2 Study (ACTIVATE) of Etigilimab and Nivolumab at 2022 ASCO Annual Meeting; Mereo Also Updates Capital Allocation and Portfolio Prioritization Plan (GlobeNewswire) -5.12%
May-26-22 05:05PM	Mereo BioPharma Announces the Presentation of Updated Data From a Phase 1b/2 Study of Etigilimab as a Poster at the 2022 American Society of Clinical Oncology Annual Meeting (GlobeNewswire) +8.77%
04:30PM	Mereo BioPharma Received Notification of Nasdaq Minimum Bid Price Deficiency (GlobeNewswire)

Mereo BioPharma Group Plc is a biopharmaceutical company, which engages in the development and commercialization of therapeutics that aim to improve outcomes for oncology and rare diseases. Its portfolio include Etigilimab (MPH-313), Alvelestat (MPH-966), Setrusumab (BPS-804), Navicixizumab (OMP-305B83), Acumapimod (BCT-197), and Leflutrozole (BGS-649). The company was founded by Denise Vera Scots-Knight, Charles Edward Sermon, Alastair Graham MacKinnon, and John P. Richard in March 10, 2015 and is headquartered in London, the United Kingdom.

Open in Screener

KPTI

Karyopharm Therapeutics Inc

Feb 13 • 04:00PM ET

8.58

-0.36 -4.03 %

Healthcare • Biotechnology • USA • NASD

KPTI Karyopharm Therapeutics Inc daily Stock Chart

Peers: BMY MRK GILD JNJ VRTX AMGN REGN PFE BIIB LLY

| Held by: VTI VXF IWC TMED BTEC CHNA

Index	-	P/E	-	EPS (ttm)	-16.62	Insider Own	7.38%	Shs Outstand	18.31M	Perf Week	37.06%
Market Cap	157.10M	Forward P/E	-	EPS next Y	-1.63	Insider Trans	-0.37%	Shs Float	16.96M	Perf Month	19.33%
Enterprise Value	326.62M	PEG	-	EPS next Q	-1.33	Inst Own	44.78%	Short Float	7.97%	Perf Quarter	53.49%
Income	-196.04M	P/S	1.08	EPS this Y	71.79%	Inst Trans	6.23%	Short Ratio	3.86	Perf Half Y	84.52%
Sales	146.07M	P/B	-	EPS next Y	67.74%	ROA	-143.71%	Short Interest	1.35M	Perf YTD	16.58%
Book/sh	-16.00	P/C	2.45	EPS next 5Y	-	ROE	-	52W High	10.38 -17.34%	Perf Year	-6.18%
Cash/sh	3.50	P/FCF	-	EPS past 3/5Y	16.03% 15.19%	ROIC	-	52W Low	3.51 144.44%	Perf 3Y	-82.77%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-2.39% 6.21%	Gross Margin	95.72%	Volatility	20.37% 11.78%	Perf 5Y	-96.24%
Dividend TTM	-	EV/Sales	2.24	EPS Y/Y TTM	-76.41%	Oper. Margin	-62.10%	ATR (14)	0.85	Perf 10Y	-89.69%
Dividend Ex-Date	-	Quick Ratio	0.94	Sales Y/Y TTM	0.57%	Profit Margin	-134.21%	RSI (14)	66.52	Recom	1.50
Dividend Gr. 3/5Y	- -	Current Ratio	0.98	EPS Q/Q	-55.63%	SMA20	27.22%	Beta	0.13	Target Price	15.40
Payout	-	Debt/Eq	-	Sales Q/Q	11.58%	SMA50	24.23%	Rel Volume	6.43	Prev Close	8.94
Employees	228	LT Debt/Eq	-	Earnings	Feb 12 BMO	SMA200	48.44%	Avg Volume	350.51K	Price	8.58
IPO	Nov 06, 2013	Option/Short	Yes / Yes	EPS/Sales Surpr.	-186.32% -2.92%	Trades		Volume	2,252,198	Change	-4.03%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-05-26	Initiated	Cantor Fitzgerald	Overweight
Oct-13-25	Upgrade	H.C. Wainwright	Neutral → Buy	$15
Jul-16-25	Downgrade	H.C. Wainwright	Buy → Neutral
Jul-11-25	Resumed	H.C. Wainwright	Buy	$27
Jan-19-23	Initiated	Piper Sandler	Overweight	$8
Nov-04-22	Upgrade	RBC Capital Mkts	Sector Perform → Outperform	$7 → $10
Feb-09-22	Upgrade	JP Morgan	Underweight → Neutral	$8
Nov-19-21	Resumed	Morgan Stanley	Equal-Weight	$27 → $10
Aug-06-21	Downgrade	SVB Leerink	Outperform → Mkt Perform	$6
Aug-06-21	Downgrade	RBC Capital Mkts	Outperform → Sector Perform	$17 → $8
Aug-06-21	Downgrade	JP Morgan	Overweight → Neutral
Jul-02-20	Initiated	Morgan Stanley	Overweight	$34
Mar-04-20	Initiated	Barclays	Overweight	$30
Jan-17-20	Downgrade	Wedbush	Outperform → Neutral
Jul-23-19	Upgrade	JP Morgan	Neutral → Overweight	$8 → $16
Jul-05-19	Reiterated	Robert W. Baird	Outperform	$15 → $25
Jul-05-19	Reiterated	H.C. Wainwright	Buy	$29 → $32
Mar-01-19	Downgrade	JP Morgan	Overweight → Neutral	$21 → $7
Feb-28-19	Reiterated	BofA/Merrill	Underperform	$15 → $5
Feb-27-19	Downgrade	BofA/Merrill	Neutral → Underperform	$15 → $5

Show Previous Ratings

Feb-12-26 02:01PM	Karyopharm Therapeutics Inc (KPTI) Q4 2025 Earnings Call Highlights: Revenue Growth Amidst ... (GuruFocus.com) +21.30%
01:02PM	Karyopharm Therapeutics Q4 Earnings Call Highlights (MarketBeat)
12:33PM	Karyopharm Therapeutics Inc. Q4 2025 Earnings Call Summary (Moby)
08:45AM	Karyopharm Therapeutics (KPTI) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
07:47AM	Karyopharm Therapeutics: Q4 Earnings Snapshot (Associated Press Finance)
07:30AM	Loading…
07:30AM	Karyopharm Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Company Progress (PR Newswire)
Feb-05-26 07:30AM	Karyopharm to Report Fourth Quarter and Full Year 2025 Financial Results on February 12, 2026 (PR Newswire)
Feb-02-26 04:05PM	Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Jan-12-26 07:00AM	Karyopharm Announces Preliminary Unaudited 2025 Revenue and Reiterates Expectation of Delivering Potentially Transformative Phase 3 Data in 2026 (PR Newswire) -5.59%
Jan-02-26 04:05PM	Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Dec-08-25 07:00AM	Karyopharm to Participate in Baird's Biotech Discovery Series (PR Newswire)
Dec-01-25 04:05PM	Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire) -6.78%
07:00AM	Karyopharm to Participate at the Piper Sandler 37th Annual Healthcare Conference (PR Newswire)
Nov-07-25 08:01PM	Karyopharm Therapeutics Inc (KPTI) Q3 2025 Earnings Call Highlights: Strategic Advances and ... (GuruFocus.com) +5.43%
Nov-03-25 04:05PM	Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire) -6.92%
07:06AM	Loading…
07:06AM	Karyopharm Therapeutics: Q3 Earnings Snapshot (Associated Press Finance)
07:00AM	Karyopharm Reports Third Quarter 2025 Financial Results and Highlights Recent Company Progress (PR Newswire)
Oct-31-25 09:35AM	Earnings To Watch: Karyopharm Therapeutics Inc (KPTI) Reports Q3 2025 Result (GuruFocus.com)
Oct-28-25 10:00AM	OmniAb, Inc. (OABI) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
Oct-27-25 07:00AM	Karyopharm to Report Third Quarter 2025 Financial Results on November 3, 2025 (PR Newswire)
Oct-17-25 09:55AM	Karyopharm Therapeutics (KPTI)'s Technical Outlook is Bright After Key Golden Cross (Zacks)
Oct-08-25 07:00AM	Karyopharm Announces Strategic Financing Transactions to Support Growth; Extends Cash Runway Into Second Quarter of 2026, Beyond Expected Top-Line Readout of Phase 3 SENTRY Trial in Myelofibrosis (PR Newswire)
Oct-01-25 04:05PM	Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire) -5.05%
Sep-24-25 03:48AM	Karyopharm Therapeutics (KPTI) Moves 27.9% Higher: Will This Strength Last? (Zacks) -8.02%
Sep-11-25 07:40AM	Karyopharm concludes enrolment in Phase III myelofibrosis treatment trial (Clinical Trials Arena) +6.92%
Sep-10-25 07:00AM	Karyopharm Announces Completion of Enrollment in the Phase 3 SENTRY Trial in Myelofibrosis (PR Newswire)
Sep-02-25 04:05PM	Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Aug-12-25 03:03AM	Karyopharm Therapeutics Inc (KPTI) Q2 2025 Earnings Call Highlights: Navigating Financial ... (GuruFocus.com) +6.63%
Aug-11-25 07:00PM	Karyopharm Therapeutics (KPTI) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
05:57PM	Karyopharm Therapeutics: Q2 Earnings Snapshot (Associated Press Finance)
07:30AM	Loading…
07:30AM	Karyopharm Reports Second Quarter 2025 Financial Results and Highlights Recent Company Progress (PR Newswire)
Aug-08-25 09:33AM	Karyopharm Therapeutics Inc (KPTI) Q2 2025 Earnings Report Preview: What To Expect (GuruFocus.com)
Aug-07-25 08:50AM	Collegium Pharmaceutical (COLL) Q2 Earnings and Revenues Surpass Estimates (Zacks)
Aug-05-25 07:00AM	Karyopharm to Report Second Quarter 2025 Financial Results on August 11, 2025 (PR Newswire)
Aug-01-25 04:05PM	Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Jul-30-25 07:35AM	United Therapeutics (UTHR) Misses Q2 Earnings Estimates (Zacks)
Jul-29-25 10:00AM	Karyopharm Therapeutics (KPTI) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release (Zacks) -5.49%
Jul-01-25 04:05PM	Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire) +5.73%
Jun-03-25 08:00AM	Karyopharm to Present at the Jefferies Global Healthcare Conference (PR Newswire)
Jun-02-25 04:05PM	Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
May-26-25 09:55AM	Here's Why Karyopharm Therapeutics (KPTI) Is a Great 'Buy the Bottom' Stock Now (Zacks)
May-19-25 09:55AM	Does Karyopharm Therapeutics (KPTI) Have the Potential to Rally 521.62% as Wall Street Analysts Expect? (Zacks)
07:00AM	Karyopharm to Participate at the 2025 RBC Capital Markets Global Healthcare Conference (PR Newswire)
May-14-25 09:31AM	Karyopharm Announces Poster Presentation on Selinexor in Myelofibrosis at the 2025 European Hematology Association Annual Meeting (PR Newswire)
May-13-25 03:08AM	Karyopharm Therapeutics Inc (KPTI) Q1 2025 Earnings Call Highlights: Promising Clinical ... (GuruFocus.com) -20.00%
May-12-25 05:25PM	Karyopharm Therapeutics (KPTI) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
04:26PM	Karyopharm Therapeutics: Q1 Earnings Snapshot (Associated Press Finance)
04:05PM	Karyopharm Reports First Quarter 2025 Financial Results and Announces New Data in Myelofibrosis that Further Suggests Selinexor May Lead to Meaningful Spleen Volume Reduction, Symptom Improvement, Hemoglobin Stabilization and Disease Modification (PR Newswire)
May-08-25 04:05PM	Karyopharm to Report First Quarter 2025 Financial Results on May 12, 2025 (PR Newswire)
May-05-25 05:10PM	Neurocrine Biosciences (NBIX) Q1 Earnings Miss Estimates (Zacks) -11.57%
May-01-25 04:05PM	Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire) +8.88%
Apr-01-25 04:05PM	Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire) -5.35% +14.69%
11:50AM	Biotech stocks slide as Marks resignation seen being negative for sector (TipRanks)
Mar-03-25 04:05PM	Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire) -8.81% -12.14%
Feb-24-25 08:40AM	Karyopharm Announces 1-for-15 Reverse Stock Split (PR Newswire)
Feb-20-25 02:03AM	Karyopharm Therapeutics Inc (KPTI) Q4 2024 Earnings Call Highlights: Navigating Revenue ... (GuruFocus.com)
01:39AM	Q4 2024 Karyopharm Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
Feb-19-25 11:45AM	Karyopharm Therapeutics (KPTI) Q4 2024 Earnings Call Transcript (Motley Fool)
08:40AM	Karyopharm Therapeutics (KPTI) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
07:45AM	Karyopharm Therapeutics: Q4 Earnings Snapshot (Associated Press Finance)
07:30AM	Karyopharm Reports Fourth Quarter and Full Year 2024 Financial Results, Announces Update to Phase 3 XPORT-EC-042 Trial and Highlights Recent Company Progress (PR Newswire)
04:59AM	Karyopharm Therapeutics Inc (KPTI) Q4 2024 Earnings Report Preview: What To Look For (GuruFocus.com)
Feb-12-25 07:00AM	Karyopharm to Report Fourth Quarter and Full Year 2024 Financial Results on February 19, 2025 (PR Newswire)
Feb-03-25 04:05PM	Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Jan-13-25 08:30AM	Karyopharm Announces Preliminary Unaudited 2024 Revenue and 2025 Objectives (PR Newswire) -6.37%
Jan-07-25 09:28AM	Why Karyopharm Therapeutics (KPTI) Is Among the Best Penny Stocks to Invest In According to Media? (Insider Monkey) -7.21%
Jan-02-25 04:05PM	Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire) +20.01%
07:00AM	Karyopharm Announces the Appointment of Lori Macomber as Chief Financial Officer (PR Newswire)
Dec-09-24 08:00AM	Karyopharm Announces the Appointment of Brendan Strong as Senior Vice President of Investor Relations and Corporate Communications (PR Newswire)
Dec-03-24 07:00AM	Karyopharm Therapeutics Provides Endometrial Cancer Program Update (PR Newswire)
Dec-02-24 07:00AM	Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Nov-25-24 07:00AM	Karyopharm to Participate at the Piper Sandler 36th Annual Healthcare Conference (PR Newswire)
Nov-20-24 04:05PM	Karyopharm Therapeutics Announces the Appointment of Chief Accounting Officer (PR Newswire)
Nov-18-24 07:00AM	Karyopharm to Present Selinexor Data at the 66th American Society of Hematology Annual Meeting and Exposition (PR Newswire)
Nov-06-24 02:08AM	Karyopharm Therapeutics Inc (KPTI) Q3 2024 Earnings Call Highlights: Navigating Growth Amidst ... (GuruFocus.com)
Nov-05-24 07:30PM	Antengene to Present Results from Two Late-Stage Studies of Selinexor Signaling Potential Clinical Breakthrough at ASH 2024 (PR Newswire) -9.36%
12:45PM	Karyopharm Therapeutics (KPTI) Q3 2024 Earnings Call Transcript (Motley Fool)
08:40AM	Karyopharm Therapeutics (KPTI) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
07:37AM	Karyopharm Therapeutics: Q3 Earnings Snapshot (Associated Press Finance)
07:30AM	Karyopharm Reports Third Quarter 2024 Financial Results and Highlights Recent Company Progress (PR Newswire)
Nov-04-24 07:14AM	Karyopharm Therapeutics Inc (KPTI) Q3 2024: Everything You Need To Know Ahead Of Earnings (GuruFocus.com)
Nov-01-24 04:05PM	Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire) -8.75%
Oct-31-24 10:02AM	Karyopharm Therapeutics (KPTI) May Report Negative Earnings: Know the Trend Ahead of Q3 Release (Zacks) +17.81%
08:00AM	Karyopharm to Report Third Quarter 2024 Financial Results on November 5, 2024 (PR Newswire)
07:30AM	Karyopharm Announces Favorable Change in Co-Primary Endpoint for Pivotal Phase 3 SENTRY Trial in Myelofibrosis (PR Newswire)
Oct-30-24 04:30PM	Karyopharm to Host Investor Event with Leading Myelofibrosis KOLs and Provide a Favorable Study Design Update on October 31, 2024 (PR Newswire)
Oct-25-24 01:01PM	Highbridge Capital Management's Strategic Acquisition of Karyopharm Therapeutics Shares (GuruFocus.com)
Oct-17-24 10:35PM	Antengene Announces XPOVIO (selinexor) Approved for Its Third Indication in South Korea, Bringing Fresh Hope to Patients with MM in the Country (PR Newswire)
Oct-01-24 04:05PM	Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire) -8.75% +16.70%
Sep-23-24 05:00AM	Antengene Announces XPOVIO (selinexor) Approved for Commercialization in Thailand (PR Newswire) -5.42%
Sep-05-24 09:35AM	Down -12.14% in 4 Weeks, Here's Why Karyopharm Therapeutics (KPTI) Looks Ripe for a Turnaround (Zacks) +11.93%
Sep-03-24 04:05PM	Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire) -5.29%
07:00AM	Karyopharm to Participate at Upcoming Investor Conferences (PR Newswire)
Sep-02-24 05:52AM	Pipeline Moves: Investigator-led oncology cell therapy trial terminated (Clinical Trials Arena)
Aug-07-24 02:56AM	Q2 2024 Karyopharm Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
Aug-06-24 10:30PM	Karyopharm Therapeutics (KPTI) Q2 2024 Earnings Call Transcript (Motley Fool)
09:25AM	Karyopharm Therapeutics (KPTI) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
08:21AM	Karyopharm Therapeutics: Q2 Earnings Snapshot (Associated Press Finance)
07:30AM	Karyopharm Reports Second Quarter 2024 Financial Results and Highlights Recent Company Progress (PR Newswire)
Aug-01-24 04:05PM	Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire) -6.58%

Karyopharm Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. The company was founded by Joseph Araujo, Ronald A. DePinho, Pamela A, Silver, Giulio Draetta, Michael G. Kauffman, and Sharon Shacham on December 22, 2008, and is headquartered in Newton, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Macomber Lori	EVP, CFO & Treasurer	Feb 03 '26	Sale	6.30	1,626	10,244	85,105	Feb 04 04:11 PM
Abate Kristin	Chief Accounting Officer	Jan 28 '26	Sale	7.03	50	352	22,622	Jan 29 04:57 PM
Abate Kristin	Chief Accounting Officer	Jan 21 '26	Sale	5.96	265	1,579	22,580	Jan 22 04:09 PM
Abate Kristin	Chief Accounting Officer	Oct 01 '25	Sale	6.30	362	2,279	10,046	Oct 03 04:56 PM
Paulson Richard A.	President and CEO	Sep 15 '25	Sale	6.43	1,257	8,083	84,046	Sep 16 04:35 PM
Mano Michael	SVP, General Counsel&Secretary	Sep 15 '25	Sale	6.43	234	1,505	21,425	Sep 16 04:34 PM
Poulton Stuart	EVP, Chief Development Officer	Sep 15 '25	Sale	6.43	401	2,578	27,710	Sep 16 04:33 PM
Rangwala Reshma	EVP & Chief Medical Officer	Sep 15 '25	Sale	6.43	408	2,623	29,390	Sep 16 04:32 PM
Cheng Sohanya Roshan	EVP & Chief Commercial Officer	Sep 15 '25	Sale	6.43	325	2,090	35,856	Sep 16 04:31 PM
Abate Kristin	Chief Accounting Officer	Sep 15 '25	Sale	6.43	23	148	10,408	Sep 16 04:30 PM
Abate Kristin	Chief Accounting Officer	Sep 03 '25	Sale	6.78	12	81	9,463	Sep 04 04:53 PM
Poulton Stuart	EVP, Chief Development Officer	Jul 29 '25	Sale	4.37	191	835	27,223	Jul 30 04:56 PM
Abate Kristin	Chief Accounting Officer	Jul 22 '25	Sale	4.00	238	952	9,475	Jul 23 05:18 PM
Paulson Richard A.	President and CEO	May 06 '25	Sale	7.12	236	1,680	82,503	May 07 05:03 PM
Rangwala Reshma	EVP & Chief Medical Officer	Apr 23 '25	Sale	6.17	419	2,585	28,853	Apr 24 04:40 PM
Paulson Richard A.	President and CEO	Apr 04 '25	Sale	3.74	245	916	82,739	Apr 07 04:59 PM
Cheng Sohanya Roshan	EVP & Chief Commercial Officer	Mar 04 '25	Sale	6.29	3,445	21,669	34,314	Mar 06 04:27 PM
Paulson Richard A.	President and CEO	Mar 04 '25	Sale	6.29	11,694	73,555	82,984	Mar 06 04:27 PM
Rangwala Reshma	EVP & Chief Medical Officer	Mar 04 '25	Sale	6.29	3,587	22,562	29,272	Mar 06 04:26 PM
Poulton Stuart	EVP, Chief Development Officer	Mar 04 '25	Sale	6.29	3,548	22,317	27,414	Mar 06 04:24 PM
Mano Michael	SVP, General Counsel&Secretary	Mar 04 '25	Sale	6.29	2,793	17,568	21,047	Mar 06 04:13 PM
Poulton Stuart	EVP, Chief Development Officer	Feb 18 '25	Sale	0.63	5,914	3,726	320,714	Feb 19 04:17 PM

MREO

Mereo Biopharma Group Plc ADR

KPTI

Karyopharm Therapeutics Inc

Upgrade your FINVIZ experience